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Abstract
Small, locally restricted renal cell carcinoma less than 4 cm in size should ideally be removed operatively by 
nephron-sparing tumour enucleation (partial kidney resection). In an increasingly elderly population, there is 
a growing trend toward parallel incidence of renal cell carcinoma and chronic renal insufficiency, with the latter’s 
associated general comorbidities. Thus, for some patients, the risks of the anaesthesia and operation increase, while 
the advantage in terms of survival decreases. Transcutaneous radio-frequency ablation under local anaesthesia, 
transcutaneous afterloading high-dose-rate brachytherapy under local anaesthesia, and percutaneous stereotactic 
ablative radiotherapy may offer a less invasive alternative therapy. Active surveillance is to be regarded as no more 
than a controlled bridging up to definitive treatment (operation or ablation), while watchful waiting, on account of 
the lack of prognostic relevance and the symptomatology of renal cell carcinoma, with its comorbidity-related, clearly 
reduced life expectancy, does not involve any further diagnostic or therapeutic measures.
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Introduction
Renal cell carcinoma (RCC) is one of the 10 most com-
mon malignomas. Its increasing incidence results from 
increased age, morbidity, and noxa, as well as from the 
increasingly widespread use of modern imaging tech-
niques [1]. In parallel, there is an increasing frequency 
of comorbidities (with negative influence upon onco-
logical disease progression) and chronic renal insuffi-
ciency (associated a priori with poorer life expectancy). 
Early-stage RCC is usually discovered by chance [2]. This 
epidemiological development and the possible side effects 
of immediate renal tumour resection call for alternative 
therapies.
“Small” renal tumour
RCC in early stages is usually asymptomatic and is therefore 
usually discovered by chance, in screening or in the diagno-
sis of other disorders. Empirically, any solid growth on the 
kidney must arouse suspicion of RCC. If imaging reveals 
typical criteria for suspicion of malignant growth, then the 
presence of RCC must be suspected. According to current 
guidelines, this would comprise a sufficient indication for 
surgical removal of the tumour, without prior confirmation 
by biopsy and histology, as long as there are no contra-indi-
cations for operation by intubation narcosis [1,2].
The term “small renal tumour” is primarily an im-
age-based morphological description of a solid growth 
 How to treat small RCC
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on the cortical renal parenchyma, without any assess-
ment of the nature, malignity, or exact location. In Eng-
lish-speaking countries this is termed “small renal mass” 
(SRM) when its diameter is 3 cm or less [3]. In continental 
Europe, a solid growth in the renal parenchyma extend-
ing up to 4 cm is referred to as a “small renal tumour” 
(German kleiner Nierentumor); this is analogous to the 
T category “cT1a, cN0, cM0; stage 1” in the 2017 UICC 
(Union Internationale Contre le Cancer) classification for 
locally restricted non-metastasised RCC [1-5]. The prog-
nostic limit of 4 cm for T1a is of historical origin and does 
not agree with recent results according to which the rates 
of growth and metastasis increase exponentially above 
a tumour size of 3 cm. Experience has been gathered in 
clinical studies up to a tumour size of 3 cm [2].
Numerous studies of the progress of T1a small renal 
tumours have shown a relatively slow annual growth, with 
a very low rate of metastasis in the first five years, but it 
must be noted that these results include a significant num-
ber of uncertainly diagnosed or benign tumours and vari-
ous RCC subtypes [6,7]. Up to 20-30% of SRMs turn out in 
histological analysis to be benign oncocytomas [8]. Chawla 
et al. performed a meta-analysis for the subgroup of biop-
sy-confirmed pT1a RCCs (n = 120) with a median tumour 
size of 2.48 cm (range 1.7-4.0 cm); they found a median 
annual growth rate of 0.35 cm (range 0.42-1.6 cm) in an 
average observation period of 30 (range 25-39) months [9]. 
Jewett et al. analysed 101 biopsy-confirmed pT1a RCCs, 
finding a progression rate of 0.13 cm/year and a metastasis 
rate of 1.1% per year in a median observation period of 
28 months [10]. Thompson et al. reported a metastasis rate 
of 0.0013% (1/720) for RCC smaller than 3 cm in a median 
observation period of 2.8 years. They found an increase in 
metastasis rate of 24% for each 1 cm tumour size increase 
[11]. Thus, tumour size is one of the most important prog-
nosis factors for the course of disease and for metastasis.
In early stages the localised RCC mainly displaces oth-
er tissue and to some extent permeates it. Often, a peritu-
moral pseudocapsule (“surgical capsule”) arises through 
compression of healthy cells in the surrounding tissue and 
of peripheral tumour cells [7]. This pseudocapsule, on av-
erage only 0.5 mm thick, is individually formed and can 
vary from a complete or incomplete pseudocapsule with 
or without tumour infiltration through to a completely 
absent pseudocapsule [12,13]. Sometimes microscopic 
satellite tumours are found in the immediate vicinity of 
the macroscopic tumour [14].
Biopsy
Confirmation of a renal tumour by biopsy and histolog-
ical analysis, prior to possible surgical treatment, is not 
routinely recommended, because it does not affect the 
choice of treatment and also because of residual diagnos-
tic uncertainty. According to the S3 guidelines, biopsy 
should be performed in cases of unclear solid growths 
on the kidney when this might affect the choice of ther-
apy, when active surveillance (AS) is being considered, 
or when ablation is due to be performed [1]. For solid 
tumours a double coaxial cylinder biopsy for histolog-
ical analysis (18G needle), outside any region of possi-
ble central tumour necrosis, is recommended. Despite 
the relatively high sensitivity and specificity of the biop-
sy-based test for a solid RCC, there is still a high rate 
(up to 20%) of false negatives or uninformative samples. 
In a meta-analysis of 1330 small (2.4-4.1 cm diameter) 
renal tumour biopsies, directed by coaxial computed to-
mography, the accuracy of targeting was 78-100% and the 
correct assignment of malignity was 86-100%; whereby 
the accuracy was 86-100% for the histological RCC sub-
type and 46-76% for the gradings [15]. A negative biopsy 
(finding of normal parenchyma) should therefore be fol-
lowed by a repeat biopsy if this is required for support of 
the choice of therapy. A further limitation of diagnosis by 
biopsy to determine the exact tumour entity is the intra-
tumoural biological heterogeneity of the RCC, although 
this can be less clearly visible for smaller tumours [16]. 
Oncocytomas, which are fundamentally classified as be-
nign, are in some cases difficult to distinguish from onco-
cytically differentiated RCC; sometimes this can only be 
done by histochemistry, and it appears possible that such 
tumours can degenerate to carcinomas [17].
The “inoperable” patient
From a purely surgical, technical standpoint, every locally 
restricted kidney tumour and every patient affected is in 
principle operable. A general, or functional inoperability 
arises through severe comorbidity that renders impossible 
either the intubation anaesthesia with muscle relaxants or 
the necessary peri-operative management, or that makes 
the immediate or subsequent risk for the patient unjusti-
fiably high. Therefore, for every patient, one must perform 
a critical risk–benefit analysis of any curative treatment, 
be it by tumour resection or by interventional ablation. 
This consideration must take account of the degree of 
invasiveness – individually and overall – of the various 
measures to be taken (Figure 1).
Figure 1. Procedures and their respective degrees of invasiveness, to be 
considered in the choice of therapy
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The term “minimally invasive” for invasive proce-
dures is frequently narrowed to refer only to the external 
access (external wound). However, in the case of kidney 
tumour, the internal access to the tumour itself and the 
damage inflicted collaterally on the renal parenchyma 
have a major influence upon the risk of perioperative 
complications and the patient’s subsequent quality of 
life. Here the patient’s age and general condition are 
particularly important for the prognosis. The incidence 
of renal tumour peaks in the seventh decade, so most 
of those affected are elderly (‘younger old’, 65-74 years; 
‘mid-old’, 75-84 years; ‘old-old’, ≥ 85 years; definitions 
by the International Society of Geriatric Oncology [SIOG] 
[18,19]). A structured geriatric assessment (Barthel Index, 
Mini-Mental-State Test, Tinetti Test) and a systematic re-
cording of comorbidities (Charlson Comorbidity Index, 
American Society of Anaesthesiologists [ASA] Score, 
degree of sarcopaenia, Eastern Cooperative Oncology 
Group [ECOG] status) allow individual decision-mak-
ing, and in about half of all cases they lead to a change in 
therapy decision [20-24] by consideration of the patient’s 
mobility, competence in everyday situations, resilience, 
and life expectancy.
Hand in hand with the patient’s age and morbidi-
ty, there is an increasing risk of peri- and post-opera-
tive complications and, moreover, a risk of death due 
to comorbidities. Thus, the complication rate in partial 
renal resection among patients under 50 years of age is 
around 30% and among 80-year-olds it is around 50%. 
In the presence of relevant comorbidities (Charlson in-
dex ≥ 2) the complication rate in partial renal resection 
and tumour nephrectomy is six times higher than in their 
absence [25]. Among the over-80s severe intervention- 
related complications occur in 35% of cases (Clavien-Dindo 
≥ III), with a mortality of around 3% [26]. Lane et al. 
investigated 537 patients with SRM; for those aged 
≥ 75 years he found no significant difference in survival 
between AS and surgical treatment (partial renal resection 
and tumour nephrectomy). In that survey 28% (n = 148) 
of the patients died within the median follow-up period of 
ca. four years, whereby 24% of the deaths had causes other 
than progressive, metastasising RCC; most were due to 
cardiovascular disorders [27]. Likewise, Sun et al. found 
no survival advantage of resecting small RCCs as regards 
carcinoma-specific mortality among patients aged over 
75 years or among those with a Charlson Comorbidity 
Index of 2 or above [28,29].
The degree of collateral damage to healthy peritu-
moral renal parenchyma caused by invasive treatment 
is correlated with the risk of chronic renal insufficiency 
or its worsening and with the associated cardiovascular 
comorbidity, with consequent reductions in the patient’s 
life expectancy and quality [30,31]. The development of 
kidney-preserving, nephron-sparing therapies is therefore 
an important goal. If renal tumour enucleation, enucleo-
resection, and sparing partial renal resection all appear 
unpromising and nephrectomy is considered highly risky, 
then for patients with chronic renal insufficiency, with 
only one kidney or with metachronic, multilocular RCC 
growth patterns (imperative indication for kidney pres-
ervation) ablative treatment should be considered as an 
alternative to resection (Figure 2).
Figure 2. Decision algorithm for treating small renal mass (SRM) or renal-cell carcinoma (RCC) 
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Damage to healthy renal parenchyma caused by inva-
sive treatment is correlated with the risk of chronic renal 
insufficiency. Decisive factors for the success and for the 
complication rate are also the position and the size of the 
renal tumour. Anatomical classification systems, such as 
the PADUA (preoperative aspects and dimensions used 
for anatomical classification) score, the R.E.N.A.L. (radi-
us, exophytic/endophytic, nearness to collecting systems 
or sinus, anterior/posterior, and location relative to polar 
lines) score, the CIndex, and the ABLATE algorithm, are 
intended to be used as aids to decide the type of treatment 
(operation and operative method; ablation and ablation 
method; AS) [32,33].
For patients with a reduced life expectancy – on the 
basis, e.g., of advanced age or very severe comorbidity 
– following the course of an asymptomatic tumour (dis-
covered by chance) would mean psychological and phys-
ical stress; this would be unnecessary and would have no 
therapeutic value. For patients of this kind, a strategy of 
waiting, without directed diagnoses or therapy, should 
be considered. This “watchful waiting” or “wait-and-see” 
procedure differs fundamentally, in indication and in con-
duct, from AS (Figure 2).
Active surveillance
If postponement of invasive treatment of locally restricted 
RCC (resection or ablation) is indicated or is desired by 
the patient, then AS is the first option. By definition, AS 
is indicated if any of the following apply:
• Immediate invasive therapy is currently medically 
contra-indicated because of temporarily elevated 
risks (such as recent myocardial infarction, need 
for multiple anticoagulant treatment, etc.) or other 
recent or current treatments (such as convalescence 
from another operation, incomplete diagnosis of an-
other prognostically relevant disorder, etc.).
• The patient wishes, for personal or social reasons, to 
postpone curatively intended therapy (family or pro-
fessional situation, holiday planning, etc.).
• The malignity is unclear, owing to ambiguous diag-
nosis, and/or the patient is afraid of side effects or 
complications of the treatment that might have a per-
manent impact upon their quality of life. In either 
case the patient may choose to postpone therapy and 
wait until there is local progression, with invasive 
treatment more urgently indicated (assuming that no 
contra-indication has arisen in the meantime). In this 
way the patient avoids “over-treatment”.
Such decisions are reached on an individual basis, if 
necessary with interdisciplinary and multicentric support. 
Nonetheless, there remains a residual uncertainty – with 
both patient and physicians – as to whether the patient 
is after all being under-treated. There always remains 
a possibility that the disease will worsen during AS to-
ward an incurable state or a more complicated treatment 
status – because of local disease progression, metastasis, 
or some other, additional disorder than might influence 
the patient’s prognosis. This perpetual unease about the 
possibility of under-treatment, or excessive postponement 
of treatment, will in itself cause a relevant reduction in 
quality of life, and for this reason a large proportion of pa-
tients decide a priori against AS or abandon AS in favour 
of a definite therapy [16].
The idea of AS arose at a time when there was a lack 
of therapeutic alternatives to operation and, consequently, 
a danger of surgical over-treatment with the associated 
risk of substantial adverse side effects and complications, 
as well as increased costs for the health-care system. The 
theoretical basis for AS is the above-mentioned low rate 
of growth and metastasis for RCCs less than 3 cm in 
size. Strictly speaking, AS at first only comprises regular 
imaging for the purpose of restaging. It should only be 
offered for RCC with a low risk of progression and me-
tastasis, after needle biopsy and histological confirmation 
of the tumour. Generally, AS is not recommended for 
renal tumours that are larger than 3 cm, are not sharply 
defined, are clearly inhomogeneous, or are found by bi-
opsy and histology to be high-grade RCC; it is also not 
recommended for patients who are young and otherwise 
healthy. However, there is no recommended scheme set-
ting out the type or interval of imaging. Imaging within 
AS should be performed at least once a year. The con-
cept of rebiopsy within the course observation of renal 
tumours during AS is likewise not established. For this 
reason, AS is generally only conducted with check-ups by 
imaging. For AS of SRM and pT1a RCC there exist data 
from retrospective studies and metaanalyses, but there is 
no information from prospective, randomised studies. 
The increasing established possibility of ablation reduces 
the scope of indication for AS.
Local ablation procedures
Percutaneous ablation techniques performed under local 
anaesthesia are increasingly filling the gap between op-
erative and conservative treatment. With the increasing 
availability of appropriate guidelines, at present more 
than 10% of small renal tumours are treated by ablation 
[1-3,34,35]. This raises a need to compare the various ab-
lation techniques with one another, and with the various 
operative methods, in respect of invasiveness, quality of 
life, complication rate, success rate (tumour control), and 
post-interventional preservation of renal function. Cur-
rently there are a lack of randomised, controlled studies 
on this subject.
The best surgical method for preserving renal paren-
chyma is enucleation of the kidney tumour (Figure 3C) 
without ischaemia and without profound local haemosta-
sis (the “surgical ideal”). In enucleoresection of kidney tu-
mour (Figure 3B) and partial renal resection (Figure 3A) 
a variable amount of the healthy peritumoral parenchyma 
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is coresected, and, as a rule, extended supply to the resec-
tion bed is performed, often with ischaemia (Figure 3). 
This should be contrasted with all non-surgical ablation 
methods; there, as a rule, the (technically inevitable) 
centrifugal effect gradient and the intra-interventional 
Figure 3. Operative techniques for removal of renal tumour (red, coresected 
healthy peritumoral parenchyma; blue, healthy parenchyma subjected to 
secondary damage by haemostatic and adaptive blood supply to the pe-
ripheral resected region). A) Partial renal resection, B) enucleoresection, 
C) enucleation (“ideal”)
movement of the tumour and/or the organ necessitate the 
inclusion of a peritumoral safety margin of 5-10 mm in 
the healthy parenchyma (Figure 4A). More recent ablation 
methods, especially non-thermal ones, are aimed towards 
tumour ablation with a sharp demarcation of the tumour, 
without damage to the peritumoral parenchyma (“abla-
tive ideal”; Figure 4B). The ablative measures are usually 
performed without ischaemia or embolisation. Thus, in 
respect of preservation of peritumoral parenchyma, the 
ablation is roughly comparable to renal tumour enucleo-
resection or enucleation, without relevant ischaemia time.
Radio-frequency ablation (RFA) and cryoablation 
(CA) are recommended in the guidelines of the German, 
European, and US-American societies for urology and ra-
diology as alternative curative treatment options for small 
renal tumours in elderly patients with high morbidity, 
when operative or anaesthesiological risks or contra-in-
dications are present [1-3]. Although these have been in 
A
B
C
Figure 4. A) Renal tumour ablation with safety margin and damage to the 
peritumoral healthy parenchyma. B) Renal tumour ablation with no safety 
margin and no damage to the peritumoral healthy parenchyma (“ideal”)
A
B
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use for some time, meaning a great deal of information is 
available, no results have been obtained in randomised, 
or even prospective, controlled studies. In a direct com-
parison of RFA with CA, neither procedure was found 
superior to the other in respect of survival (whether dis-
ease-related mortality, or progression-free or overall sur-
vival) [36]. Each has its own limitations on account of the 
thermoablative effect (heat-sink effect, cold-sink effect, 
thermal coagulative collateral damage). In the interests 
of more direct application and haemostasis, CA is pref-
erentially used, by operative laparoscopy under general 
anaesthesia; consequently, it has no practical advantage 
over tumour resection, despite having the same risk of 
complications and being technically more complex than 
percutaneous RFA under local anaesthesia and analgose-
dation [36].
Percutaneous radio-frequency thermoablation
Percutaneous RFA is the interventional ablation meth-
od most frequently used as an alternative, non-surgical 
treatment of RCC. It is technically simple and relatively 
quick (the ablation takes 10-20 min) under fluoroscopy 
(CT or magnetic resonance imaging – MRI) with anal-
gosedation. RFA is a hyperthermal ablation procedure: 
a high-frequency (375-480 kHz) alternating potential 
is applied through suitably placed needle electrodes; 
the resulting ion current and Joule heating to 60-100°C 
leads to coagulation necrosis [36]. The electrodes used 
are mostly expandable electrodes with multi-array tip of 
various sizes. A 5-10 mm safety margin is recommended 
for ablation. The primary success rate of RFA in SRM is 
between 90% and 100%, depending upon the tumour’s 
size and position; for technical reasons, this rate is high-
er for corticoperipheral SRMs and those below 3 cm in 
size [27,37-40]. Various studies have reported local re-
currence for pT1a-RCC between 2% and 12% in the first 
five years after RFA [38,41-45]. Moreover, RFA allows 
repetition, with a secondary success rate rising to nearly 
100% [46]. Complications following renal RFA (0-19% of 
cases) are mostly mild [1,39,40,42,43,47]. Overall, RFA 
yields results comparable to those of partial renal resec-
tion, although no randomised studies have yet been de-
scribed [1-3,43,48]. When long-term results are known, 
the indication may well be expanded to include RFA for 
treating T1a RCC. However, there is a limitation for renal 
tumours located centrally, directly adjacent to the hilus 
and the pelvicalyceal system or to large blood vessels. 
The strong vascularisation of RCC frequently leads, on 
account of the heat-sink effect (see above), to incomplete 
ablation [49,50]. RFA is not recommended in the vicinity 
of the pelvicalyceal system or the ureter on account of the 
risk of perforation, fistulation, or stricture [1,2,42]. These 
restrictions on the indication can be circumvented by al-
ternative, non-thermal ablation methods (Figure 5). 
Alternative percutaneous non-thermal ablation methods
Up to now, alternative ablation techniques have been of 
a largely experimental nature and have not been recom-
mended in guidelines [1-3]. In particular, non-thermal 
procedures might be able to avoid thermal collateral dam-
age and thus lead to expansion of the range of indications 
for RCC ablation. However, irreversible electroporation 
at its present stage of development is technically high-
ly demanding and also requires intubation anaesthesia 
with complete muscular relaxation; therefore, it does not 
offer any clear advantage [51-53]. Early results of ongo-
ing studies suggest a high potential for transcutaneous 
brachytherapy in the afterloading procedure and for ste-
reotactic percutaneous radiotherapy. In particular, these 
radiotherapeutic procedures allow treatment without the 
need for anaesthesia – even in cases of large and irregu-
larly shaped renal tumours, while taking account of res-
piratory movements of the kidneys.
In high-dose-rate brachytherapy (HDRBT), the 
target tissue is exposed to very high doses of radiation 
(> 12 Gy/h) by temporarily inserted radiation sources 
(preferentially the bemitting nuclide iridium192). After 
positioning of the BT catheter by Seldinger’s method and 
analgosedation, the radiation sources are introduced for 
some 20-90 minutes and then removed; this follows exact, 
individual, three-dimensional dose planning and calcu-
lation of the duration of exposure, taking into account 
the target tumour volume. The characteristic fall-off in 
radiation intensity means that undesired high exposure 
of the surrounding tissue and the neighbouring organs 
is avoided. Currently, BT of RCC is being investigated in 
two ongoing prospective phase I and phase II studies in 
the Department of Radiology and Nuclear Medicine at 
Magdeburg University Hospital in Germany [36]. Pre-
liminary results suggest good controllability and a good 
response of the RCC. Analogously, a high local tumour 
control in HDRBT, using the same techniques, has been 
found for adrenal-gland malignomas [54] (Figure 6).
Modern stereotactic ablative radiotherapy (“stereotac-
tic ablative body radiotherapy” – SABR) allows precise, 
focussed, hypofractionated irradiation (“radiosurgery”, 
24-40 Gy over one to five fractions in single doses of 
Figure 5. Radiofrequency ablation (RFA) of a renal cell carcinoma of the 
right kidney, A) pre-treatment CT scan of the right kidney with upper pole 
small renal mass (yellow arrow), B) CT scan of RFA probe (yellow arrow) 
with artificial pneumoperitoneum (red arrow) to displace the colon to avoid 
bowel necrosis/perforation, C) posttreatment CT scan immediately after RFA 
with complete necrosis of the ablation zone and tumour (yellow arrow) and 
the artificial pneumoperitoneum
A B C
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4-25 Gy each) in the cytotoxic region for RCC that is 
otherwise resistant to conventional radiotherapy. Siva 
et al. studied 223 patients treated with SABR (118 with 
single-fraction and 105 with multi-fraction treatments) 
and observed local control of 97.8% after four years, with 
only mild toxicity (grades 1 and 2, 35.6%; grades 3 and 4, 
1.3%) [55]. Siva et al. reported from 33 patients with 62% 
T1b, 35% T1a, and 3% T2a RCC that freedom from local 
progression, distant progression, and overall survival rates 
at two years were 100%, 89%, and 92%, respectively. The 
mean baseline glomerular filtration rate was 55 ml/min, 
which decreased to 44 ml/min at one and two years 
(p < 0.001) [56]. In the German guidelines this procedure 
is already mentioned as a potential future treatment op-
tion [1].
Practical summary
• For patients aged over 75 years, with small RCC 
(< 3-4 cm), and with heightened comorbidity or 
advanced chronic renal insufficiency, an individual 
risk–benefit assessment should be performed be-
tween operative tumour resection on the one hand 
(as gold standard: enucleation, partial resection) and 
interventional ablation on the other (as an alternative 
treatment).
• Percutaneous biopsy, for histological confirmation 
and risk stratification, must be performed before ab-
lation or AS.
• AS, a postponement of curative treatment with close 
imaging-based observation, is only to be recom-
mended for selected patients with a low-risk RCC 
smaller than 3 cm.
• As an alternative, guideline-based ablation procedure 
for treating SRM or RCC, percutaneous thermoab-
lative RFA without general anaesthesia has the most 
advantages.
• Among the ablation methods hitherto regarded as 
experimental, HDBRT and SABR – both non-ther-
mal radiotherapeutic procedures – at present show 
the greatest potential.
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Figure 6. High-dose-rate brachytherapy (HDR-BT) of a renal cell carcinoma 
of the right kidney, A) pre-treatment CT scan of the right kidney with lower 
pole small renal mass (yellow arrow), B) CT scan of brachytherapy probe 
with treatment planning (isodose volume calculations) of high-dose-rate 
brachytherapy (afterloading), C) posttreatment CT scan 2 years after HDR-BT 
with involution of the tumour (yellow arrow)
A B C
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